Idioma: Español
Referencias bibliográficas: 208
Paginas: 5-44
Archivo PDF: 323.67 Kb.

RESUMEN

Se dan a conocer las guías para el diagnóstico y el tratamiento de los Síndromes Coronarios Agudos sin elevación del segmento ST [SICA SESST: Angina inestable e infarto agudo del miocardio no Q] en México. Por iniciativa de la Sociedad Mexicana de Cardiología [Directiva 2000- 2002] se realiza por primera vez el Consenso Nacional sobre SICA SESST con fundamento en RENASICA [Registro Nacional de Síndromes Coronarios Agudos]. Los lineamientos para el diagnóstico y para el tratamiento derivadas en esta oportunidad son aquellas que provienen de la información obtenida de los principales meta - análisis, de estudios aleatorizados o bien de recomendaciones de grupos de expertos en esta temática de la cardiopatía isquémica aguda. Las guías finales del diagnóstico y del tratamiento consignadas en este documento son las que se sugieren por este Grupo de trabajo, como las normas más apropiadas para el manejo contemporáneo de los SICA SESST en México. No se pretende de ninguna manera imponerlas. La conducta final en determinado enfermo deberá ser tomada por el médico de acuerdo a la condición clínica que prive en ese momento. La versión dada a conocer, de este Consenso deberá ser actualizada necesariamente en la misma medida como se avanza en el conocimiento de los SICA SESST en un futuro próximo cercano por cardiólogos mexicanos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Registro Nacional de los Síndromes Isquémicos Coronarios Agudos [RENASICA]: Sociedad Mexicana de Cardiología. Por el Grupo Cooperativo RENASICA. Arch Inst Cardiol Méx 2002; 72: S46-S65.

2. Braunwald E, Antman EM, Beasley JW, Califf RM , Cheitlin MD, Hochman JS, et al: ACC/AHA guidelines for the managements of patients with unstable angina and non-ST segment elevation MI: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Unstable Angina). J Am Coll Cardiol 2000; 36: 970-1062.

3. Antman EM, Bassand JP, Klein W, Ohman M, López Sendón JL, Rydén L, et al: Myocardial Infarction redefined-a consensus document of the Joint European Society of Cardiology/american College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000; 36: 959-69.

4. Bertrand ME, Simmons ML, Fox KAA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ: Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21: 1406-1432.

5. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N: Ability of minor elevations of troponins I and T to predict Benefit From an Early Invasive Strategy in Patients With Unstable Angina and Non-ST Elevation Myocardial Infarction. Results From a Randomized Trial. JAMA 2001; 286: 2405-2412.

6. Quin JM, Moliterno DJ: Troponins in Acute Coronary Syndromes. More TACTICS for an Early Invasive Strategy. JAMA 2001; 286: 2461-62.

7. Lindahl B, Diderholm E, Lagerqvist B, Venge P, Wallentin L, e investigadores del FRISC II: Mechanisms Behind the prognostic Value of Troponin T in Unstable Coronary Artery Disease: A FRISC II Substudy. J Am Coll Cardiol 2001; 38: 979-86.

8. Antman EM: Troponin Measurements in Ischemic Heart Disease: More Than Just a Black and White Picture. J Am Coll Cardiol 2001; 38: 987-90.

9. Antman EM, Cohen M, Bernink PJLM, McCabe CH, Horacek T, Papuchis G, et al: The TIMI risk score for unstable angina - non ST-elevation MI: a method for prognostication and therapeutic decision-making. JAMA 2000; 284: 835- 42.

10. Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E: An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes . Application of the TIMI Risk Score for UA/NSTMI in PRISM-PLUS. Eur Heart J 2002; 23: 223-229.

11. Langer A, Goodman SG, Topol E, Charlesworth A, Skene AM, Wilcox RG, Armstrong PW: Late assessment of Thrombolytic Efficacy (LATE ) Study: Prognosis in Patients With Non-Q wave Myocardial Infarction. J Am Coll Cardiol 1996; 27: 1327-32.

12. Furman MI, Dauerman HL, Goldberg RJ, Yarzbeski J, Lessard D, Gore JM: Twenty-Two Year (1975 to 1997) Trens in the Incidence, In -Hospital and long-term Case fatality Rates From Initial Q-wave and non-Q-wave Myocardial Infarction: A Multi -Hospital,Community -Wide Perspective. J Am Coll Cardiol 2001; 37: 1571-1580.

13. Campeau L: Grading of angina pectoris (letter). Circulation 1976; 54: 522-523.

14. Savonitto S, Ardissino D, Granger C, Morando G, Prando MD, Mafrici A, et al: Prognostic value of the admission electrocardiogram in acute coronary syndromes JAMA 1999; 281: 707-713.

15. Cannon CP, Thompson B, McCabe C, Mueller HS, Kirshenbaum JM, Herson S, et al: Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: an analysis from the thrombolysis in myocardial ischemia (TIMI) III trials. Am J Cardiol 1995; 75: 977-981.

16. Calvin JE, Klein LW, VandenBerg BJ, Meyer P, Condon JV, Snell RJ, et al: Risk Stratification in Unstable Angina. Prospective validation of the Braunwald Classification. JAMA 1995; 273: 136-141.

17. Mahadevan VS, Adgey AAJ: ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease- the FRISC II ECG substudy. Eur Heart J 2002; 23: 3-5.

18. Causas de mortalidad en México 2000. Estadísticas de Mortalidad, Secretaría de Salud. http://www.ssa.gob.mx.

19. Braunwald E: Unstable angina: an etiologic approach to management. Circulation 1998; 98: 2219-2222.

20. Goldstein JA, Demetriou D, Grines C, Pica M, Shoukfeh M, O’Neill WW: Multiple complex coronary plaques in patients with acute myocardial infarction N Engl J Med 2000; 343: 915-922.

21. Gavin BJ, Maxwell L, Edgar S: Microvascular Involvement in Cardiac Pathology. J Mol Cell Cardiol 1998; 30: 2531-2540.

22. Michaels AD, Gibson CM, Barron HV: Microvascular Dysfunction in Acute Myocardial Infarction: Focus on the Roles of Platelet and Inflammatory Mediators in the No-Reflow Phenomenon. Am J Cardiol 2000; 85: 50B-60B.

23. Topol EJ, Yadav JS: Recognition of the importance of embolization in Atherosclerotic Vascular Disease. Circulation 2000; 101: 570-580.

24. Frink RJ, Ostrach LH, Rooney PA, Rose J: Coronary thrombosis, ulcerated atheroesclerotic plaques and platelet/fibrin microemboli in patients dying with acute coronary disease: a large autopsy study. J Clin Invest 1990; 2: 199-210.

25. Braunwald E: Unstable angina: a classification. Circulation 1989; 80: 410-14.

26. Selker HP, Beshansky JR, Griffith JL, Aufderheide TP, Ballin DS, Bernard SA, et al: Use of acute cardiac ischemia time-insensitive predictive instrument] ACI-TIPI] to assist with triage of patients with chest pain or other symptoms suggestive of acute cardiac ischemia: a multicenter, controlled trial. Ann Intern Med 1998; 129: 845-855.

27. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, et al: ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 1999; 33: 2092-2197.

28. Márquez-Murillo MF, Férez SS: Cardiopatía Isquémica Crónica. PLAC-cardio 3 [Programa Latinoamericano de actualización continua en Cardiología] Sociedad Mexicana de Cardiología-Sociedad Interamericana de Cardiología Libro 10. Intersistemas, México. 2002: 654-657.

29. Pryor D, Shaw Mc, Cants C, Kerry LL, Mark DB, Herrel FE, et al: Value of the hystory and physical in identifying patients at increased risk of coronary disease. Ann Intern Med 1993; 118: 81- 90.

30. Iturralde PT: Arritmias Cardíacas. El electrocardiograma en la cardiopatía isquémica. 2da Edición. México. McGraw-Hill Interamericana, 2002 p. 693-720.

31. De Michelli A, Medrano GA: El electrocardiograma y el vectocardiograma en el infarto del miocardio. La Prensa Médica Mexicana, México, 1971, 160-171.

32. Roberts R, Fromm RE: Management of acute coronary syndromes based on risk stratification by biochemical markers: an idea whose time has come. Circulation 1998; 98: 1831-1833.

33. Mair J, Morandell D, Genser N, Lechleitner P, Dienstl F, Purchendorf B: Equivalent early sensitivities of myoglobin, creatine kinase MB mass, creatine kinase isoform ratios, and cardiac troponins I and T for acute myocardial infarction. Clin Chem 1995; 41: 1266-1272.

34. Hamm CW, Goldman BU, Heeschen C, Kreymann G, Berger J, Meinertz T: Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. New Enlg J Med 1997; 337: 1648-1653.

35. Antman EM, Sacks DB, Rifai N, McCabe CH, Cannon CP, Braunwald E: Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis In Myocardial Infarction [TIMI] 11A substudy. J Am Coll Cardiol 1998; 31: 326-330.

36. Hamm CW, Ravkilde J, Gerhardt W, Jorgensen P, Peheim E, Ljungdahl L, et al: The prognostic value of serum troponin T in unstable angina. New Engl J Med 1992; 327: 146-150.

37. Juárez UH, Lasses LA, Martín RP, Luna JG, López MCR, Chuquiure EV, et al: Utilidad de la determinación cualitativa rápida de troponina T, fracción MB de creatina fosfocinasa y mioglobina en los síndromes isquémicos coronarios agudos. Arch Inst Cardiol Méx 1998; 68: 473-481.

38. Hamm CW, Braunwald E: A classification of unstable angina revisited. Circulation 2000; 102: 118-122.

39. Cannon CP, O’Gara PT: Critical Patways for acute coronary syndromes. In : Cannon CP ed. Management of acute coronary syndromes. Totowa, NJ: Humana Press; 1999: 611-627.

40. Armstrong PW: Stable Isquemic Syndromes. En: Topol EJ, ed. Textbook of cardiovascular medicine. Philadelphia, PA: Lippincott-Raven; 1998: 333-364.

41. Guadalajara BJ. Cardiología. 5ª Ed. México. McGraw-Hill. Interamericana, 1997.

42. Martínez Sánchez C: Insuficiencia Cardíaca. PLAC Cardio 3 [Programa Latinoamericano de actualización continua en Cardiología]. Sociedad Mexicana de Cardiología-Sociedad Interamericana de Cardiología. Libro 9. México. Intersistemas, 2002: 592-601.

43. Dellborg M, Gustaffsson G, Swedberg K: Buccal versus intravenous nitroglycerin in unstable angina pectoris. Eur J Clin Pharmacol 1991; 41: 5-9.

44. ISIS-4 [Fourth International Study of Infarct Survival] Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.

45. Figueras J, Lidon R, Cortadellas J: Rebound myocardial ischemia following abrupt interruption of intravenous nitroglycerin infusion in patients with unstable angina at rest. Eur Heart J 1991; 12: 405-411.

46. Cheitlin MD, Hutter AMJ, Brindis RG, Ganz P, Kaul S, Russell RO, et al: ACC/AHA expert consensus document: use of sildenafil [Viagra] in patients with cardiovascular disease: American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999; 33: 273-282.

47. Armstrong PW: Stable Ischemic Syndromes. En: Topol EJ, ed. Textbook of cardiovascular medicine. Philadelphia, PA: Lippincott-Raven; 1998: 351-353.

48. White HD: Unstable Angina: Ischemic Syndromes. En: Topol EJ, ed. Textbook of cardiovascular medicine. Philadelphia, PA: Lippincott-Raven; 1998: 365-393.

49. Furberg CD, Psaty BM, Meyer JV: Nifedipine: dose -related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.

50. Gibson RS, Boden WE, Theroux P, Straus HD, Pratt CM, Gheorghiade M, et al: Diltiazem and reinfarction in patients with non Q wave myocardial infarction: results of a double- blind, randomized, multicenter trial. N Engl J Med 1986; 315: 423-429.

51. Lubsen J, Tijssen JG: Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial [HINT]. Am J Cardiol 1987; 60: 18A-25ª.

52. Pepine C, Faich G, Makuch R: Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol 1998; 21: 633-641.

53. Held PH, Yusuf S, Furberg CD: Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989; 299: 1187-1192.

54. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet theraphy in various categories of patients. [erratum appears in BMJ 1994; 308: 1540]. BMJ 1994; 308: 81-106.

55. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. [erratum appears in N Engl J Med 1997; 337: 356] N Engl J Med 1997; 336: 973-979.

56. Lewis HDJ, Davies JW, Archibald DG, Phil M, Steinke WE, Smitherman TC, et al: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403.

57. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, et al: Aspirin, sulfinpyrazona, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1169-1175.

58. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Lévy G, et al: Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1111.

59. Schror K: The basic pharmacology of ticlopidine and clopidogrel. Platelets 1993; 4: 252-261.

60. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, et al: Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter trial. The Studio della Ticlopidina nell’Angina Instabile Group. Circulation 1990; 82: 17-26.

61. Love BB, Biller J, Gent M: Adverse hematological effects of ticlopidine. Prevention, recognition and management. Drug Safety 1998; 19: 89-98.

62. CAPRIE Steering Committee: A randomized, blinded, trial of clopidogrel versus Aspirin in patients at risk of ischemic Events [CAPRIE]. Lancet 1996; 348: 1329-1339.

63. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, et al: Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773-1777.

64. Muller C, Buttner HJ, Petersen J, Roskamm H: A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary stents. Circulation 2000; 101: 590-593.

65. The SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after coronary syndromes: a randomized trial. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet 2000; 355: 337-345.

66. Boerma E, Harrington RA, Moliterno DJ, White H, Teroux P, Van de Werf F, et al: Platelet glycoprotein II b/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized trials. Lancet 2002; 359: 189-198.

67. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-830.

68. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, et al: Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in non prior aspirin users: primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994; 89: 81-88.

69. Telford Am, Wilson C: Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981; 1: 1125-1128.

70. Williams DO, Kirby MG, McPearson K, Phear DN: Anticoagulant treatment of unstable angina. Brit J Clin Pract 1986; 40: 114-116.

71. Theroux P, Waters D, Qiu S, McCans J, de Guise P, Jumeau M: Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993; 88: 2045-2048.

72. Neri SG, Gensini GF, Poggesi L, Trotta F, Modesti PA, Boddi M, et al: Effect of heparin, aspirin, or alteplase in reduction of myocardial ischemia in refractory unstable angina. [erratum appears in Lancet 1990; 335: 868] Lancet 1990; 335: 615-618.

73. Holdright D, Patel D, Cunningham D, Thomas R, Hubbard W, Hendry G, et al: Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994; 24: 39-45.

74. Cohen M, Adams PC, Hawkins L, Bach M, Fuster V: Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction [a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group]. Am J Cardiol 1990; 66: 1287-1292.

75. Oler A, Whooley MA, Oler J, Grady D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996; 276: 811-815.

76. Theroux P, Waters D, Lam J, Juneau M, McCans J: Reactivation of unstable angina after discontinuation of heparin. N Engl J Med 1992; 327: 141-145.

77. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie GG, et al: Comparison of low -molecular-weight heparin with unfractioned heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin In unstable Coronary artery disease study [FRIC]. [erratum appears in Circulation 1998; 97: 413] Circulation 1997; 96: 61-68.

78. The FRAXIS study group. Comparison of two treatments duration [6 days and 14 days] of a low molecular weight heparin with a 6-day treatment of unfractioned heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAXIS [FRAXiparine in Ischaemic Syndrome]. Eur Heart J 1999; 20: 1553-1562.

79. Xiao Z, Theroux P: Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with a low-molecular-weigth heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-256.

80. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Tech M, et al: Heparin -induced thrombocytopenia in patients treated with low -molecular-weigth heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.

81. Fragmin and Fast Revascularization during InStability in Coronary artery disease Investigators: Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicentre study. Lancet 1999; 354: 701-707.

82. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, et al: A comparison of low-molecular weight heparin with unfractioned heparin for unstable coronary artery disease . Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-452.

83. Antman EM, McCabe CH, Gurfinkel EP, Turpie AGG, Bernink PJLM, Salein D, et al: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction [TIMI] 11B trial. Circulation 1999; 100: 1593-1601.

84. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, et al: Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B –ESSENCE meta-analysis. Circulation 1999; 100: 1602-1608.

85. Gurfinkel EP, Manos EJ, Mejail RI, Cerdá MA, Duronto EA, García CN, et al: Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995; 26: 313-318.

86. Fragmin during Instability in Coronary Artery disease [FRISC] study group: Low -molecular -weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-568.

87. Ross AM, MolhoeK P, Lundergan C: Randomized comparison of enoxaparin, a low-molecular -weight heparin, with unfarctionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of heparin and aspirin reperfusion therapy (HEART II). Circulation 2001; 22: 13.

88. Antman EM, Louwerenburg HW, Baars HF, Wesdorp JCL, Hamer B, Bassand JP, et al for the ENTIRE-TIMI 23 Investigators: Enoxaparin as adjunctive antithrombin therapy for ST-Elevation myocardial infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI ) 23 trial. Circulation 2002; 105: 1642-1649.

89. TIMI III B Study group: Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and no-Q-wave myocardial infarction: results of the TIMI III B trial. Thrombolysis in Myocardial Ischemia. Circulation 1994; 89: 1545-1556.

90. Aroesty J, Weintraub R, Paulin S, O’Grady GP: Medically refractory unstable angina pectoris. Hemodynamic and angiographic effects of intraaortic balloon counterpulsation. Am J Cardiol 1979; 43: 883-888.

91. Kantrowitz A, Masfic T, Freed P, Rubenfire M, Wajszczuk W, Schork A: Intraaortic balloon pumping 1967 through 1982: analysis of complications in 733 patients. Am J Cardiol 1986; 57: 976-983.

92. Rouan GW, Lee TH, Cook EF, Brand DA, Weisberg MC, Goldman L: Clinical characteristics and outcome of acute myocardial infarction in patients with initially normal or nonspecific electrocardiograms (a report from the Multicenter Chest Pain Study). Am J Cardiol 1989; 64: 1087-92.

93. Zaacks SM, Liebson PR, Calvin JE, Parrillo JE, Klein LW: Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications? J Am Coll Cardiol 1999; 33: 107-18.

94. Lee TH, Cook EF, Weisberg MC, Rouan GW, Brand DA, Goldman L: Impact of the availability of a prior electrocardiogram on the triage of the patient with acute chest pain. J Gen Intern Med 1990; 5: 381-8.

95. Fesmire FM, Percy RF, Wears RL: Diagnostic and prognostic importance of comparing the initial to the previous electrocardiogram in patients admitted for suspected acute myocardial infarction. South Med J 1991; 84: 841-6.

96. Adams JE, Abendschein DR, Jaffe AS: Biochemical markers of myocardial injury: is MB creatine kinase the choice for the 1990s? Circulation 1993; 88: 750-63.

97. Gómez-Villalobos M, Vargas-Barrón J, Romero-Cárdenas A, Rijlaarsdam M, Keirns C, Lupi-Herrera E, et al: Right Atrial and Ventricular Infarction: Evaluation with Transesophageal Echocardiography. Echocardiography 1995; 12: 129-137.

98. Battler A, Slutsky R, Karliner J, Froelicher V, Ashburn W, Ross J Jr: Left ventricular ejection fraction and first third ejection fraction early after myocardial infarction: value for predicting mortality and morbidity. Am J Cardiol 1980; 45: 197-202.

99. Zornoff LAM, Skali H, Pfeffer MA, St. John SM, Rouleau JL, Lamas GA, et al for the SAVE Investigators: Right ventricular dysfunction and risk of heart failure and mortality after myocardial infarction. J Am Coll Cardiol 2002; 39: 1450-1455.

100. Lupi-Herrera E, Lasses LA, Cosio-Aranda J, Chuquiure-Valenzuela E, Martínez-Sánchez C, Ortíz P, et al: Acute right ventricular infarction: clinical spectrum, results of reperfusion therapy and short-term prognosis. Coron Artery Dis 2002; 13: 57-64.

101. González-Chon O: Complicaciones en la Terapia postquirúrgica cardiovascular. Manual Moderno, México 2002: 139-52.

102. Vargas Barrón J: Ecocardiografía de modo M, bidimensional y Doppler México. Salvat Mexicana de Ediciones SA de CV, 1985: p. 263-285.

103. Nyman I, Areskog M, Areskog NH, Swahn E, Wallentin L: Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease. The RISC Study Group. J Intern Med 1993; 234: 293-301.

104. Gibbons RJ, Balady GJ, Beasley JW, Bricker JT, Duvernoy WFC, Froelicher VF, et al: ACC/AHA guidelines for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [Committee on Exercise Testing]. J Am Coll Cardiol 1997; 30: 260-311.

105. Cheitlin MD, Alpert JS, Armstrong WF, Aurigemma GP, Beller G, Bierman FZ, et al: ACC/AHA guidelines for the clinical application of echocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [Committee on clinical application of echocardiography]. Developed in collaboration with the American Society of Echocardiography. Circulation 1997; 95: 1686-1744.

106. Ritchie JL, Bateman TM, Bonow RO, Crawford MH, Gibbons RJ, Hall RJ, et al: Guidelines for the clinical use of radionuclide imaging. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [Committee on clinical application on the assessment of diagnostic and therapeutic cardiovascular procedures] [Committee on Radionuclide Imaging]. Developed in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol 1995; 25: 521-547.

107. Mark DB, Shaw L, Harrel FEJ, Hlatky MA, Lee KL, Bengston JR, et al: Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med 1991; 325: 849-853.

108. Marwick TH, Anderson T, Williams MJ, Haluska B, Jacques AM, Pashkow F, Thomas JD: Exercise echocardiography is an accurate and cost-efficient technique for detection of coronary artery disease in women. J Am Coll Cardiol 1995; 26: 335-341.

109. Férez SM, Shapiro M: Adaptación cardiovascular a la prueba de esfuerzo. Electrocardiografía Dinámica. México. Salvat Editores, 1981: 23-39.

110. Bukhoff D, Jones J, Becker L: Variability of Myocardial Perfusion Defects Assessed by Thallium-201 Scintigraphy in Patients With Coronary Artery Disease Not Amenable to Angioplasty or Byppass Surgery. J Am Coll Cardiol 2001; 38: 1033-1039.

111. Cannon C: American College of Cardiology Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology Task Force on Clinical Data Standards. J Am Coll Cardiol 2001; 38: 2114-2130.

112. Choi K, Kim R, Gubernikoff G, Vargas J, Parker M, Judd R: Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation 2001; 104: 1101-1107.

113. Beller G: Assessing prognosis by means of radionuclide perfusion imaging: What technique and which variables should be used? J Am Coll Cardiol 1998; 31: 1286-1290.

114. Klein C, Nekolla S, Bengel F, Momose M, Sammer A, Haas F, et al: Assessment of Myocardial Viability With Contrast-Enhanced Magnetic Resonance Imaging: Comparison With Positron Emission Tomography. Circulation 2002; 105: 162-167.

115. Reeder S: Advanced Cardiac MR imaging of ischemic heart disease. Radiographics 2000; 21: 1047-1074.

116. Laham R, Simons M, Pearlman J, Ho K, Baim D: Magnetic Resonance Imaging Demonstrates Improved Regional Systolic Wall Motion and Thickening and Myocardial Perfusion of Myocardial Territories Treated by Laser Myocardial Revascularization. J. Am Coll Cardiol 2002; 39: 1-8.

117. Mazzanti M, Germano G, Kiat H, Kavangh PB, Alexánderson E, Berman DS: Identification of severe and extensive coronary artery disease by automatic measurement of transient ischemic dilation of the left ventricle in dual isotope SPECT. J Am Coll Cardiol 1996; 27: 1612-20.

118. Alexánderson E, Varguez V, Bialostozky D: Valoración simultánea de la perfusión miocárdica y la viabilidad miocárdica a través del estudio de 2 isótopos. Experiencia inicial en México y América Latina. Arch Inst Cardiol Mex 1997; 67: 48-90.

119. Alexánderson E, Gómez-León A, García LJ, Sánchez E, Preciado A, Suárez P, et al: Detección de isquemia miocárdica mediante la administración de adenosina y técnica SPECT. Experiencia inicial en México. Arch Inst Cardiol Mex 1999; 69: 546-553.

120. Alexánderson E, Rubistein J, Unzek S, Serratos JE, Motola D, Arroyo A, et al: Análisis de los primeros 1,600 casos estudiados con método de dos isótopos en México. Arch Inst Cardiol Mex 2000; 70: 234-240.

121. Puente A, Alexánderson E, Arroyo A, Victoria D: Evaluación simultánea de la perfusión miocárdica y función ventricular utilizando Tl-201 en reposo/Tc99 tetrofosmin en esfuerzo mediante SPECT sincronizado. Experiencia inicial en Latinoamérica. Arch Inst Cardiol Mex 2000; 70: 448-455.

122. Martínez Ríos MA: Cateterismo Cardíaco. Diagnóstico y Tratamiento de las Cardiopatías. Cardiopatía Isquémica. México. Editorial Trillas. 1990: 169-202.

123. Williams DO, Braunwald E, Thompson B, Sharaf BL, Buller CE, Knatterud GL: Results of percutaneous transluminal coronary angioplasty in unstable angina and non -Q- wave myocardial infarction: observations from the TIMI IIIB trial. Circulation 1996; 94: 2749-2755.

124. Moreyra AE, Palmeri ST, Wilson AC, Kulkarni A, Kulkarni R: Coronary angioplasty in unstable angina: contemporary experience. Can J Cardiol 1995; 11: 385-390.

125. Stammen F, De Scheerder I, Glazier JJ, Van Lierde J, Vrolix M, Willerms JL, et al: Immediate and follow- up results of the conservative coronary angioplasty strategy for unstable angina pectoris. Am J Cardiol 1992; 69: 1533-1537.

126. Kamp O, Beatt KJ, De Feyter PJ, van den Brand M, Suryapranata H, Luijten HE, et al: Short, medium and log- term follow-up after percutaneous transluminal coronary angioplasty for stable and unstable angina pectoris. Am Heart J 1989; 117: 991-996.

127. Khan MM, Ellis SG, Aguirre FV, Weisman HF, Wildermann NM, Califf RM, et al: Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial . EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol 1998; 31: 31-36.

128. Malosky SA, Hirshfeld JWJ, Herrmann HC: Comparison of results of intracoronary stenting in patients with unstable vs stable angina. Cathet Cardiovasc Diagn 1994; 31: 95-101.

129. Marzocchi A, Piovaccari G, Marrozzini C, Ortolani P, Palmerini T, Branzi A, Magnani B: Results of coronary stenting for unstable versus stable angina pectoris. Am J C ardiol 1997; 79: 1314-1318.

130. Topol EJ, Califf RM, Weisman HF, Ellis ES, Tcheng JE, Worley S, et al: Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six moths. The EPIC Investigators. Lancet 1994; 343: 881- 886.

131. The RESTORE Investigators: Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Circulation 1997; 96: 1445-1453.

132. RITA 2 trial participants: Coronary angioplasty versus medical treatment for angina: the second randomized intervention treatment of angina. Lancet 1997; 350: 461-468.

133. Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, et al: Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abxicimab [c7E3 Fab] among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. J AM Coll Cardiol 1997; 30:149-156.

134. Boden WE, O’Rourke RA, Crawford MH, Blaustein AS, Deedwania PC, Zoble RG, et al: Outcomes in patients with acute non - Q- wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy: Veterans Affairs non- Q -wave Infarction Strategies in Hospital [VANQWISH] Trial Investigators. N Engl J Med 1998; 338: 1785-1792.

135. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al: for the Treat Angina with Aggrastat and Determine Cost of Therapy With an Invasive or Conservative Strategy [TACTICS] TIMI 18 Investigators: Ability of minor elevations of troponins I and T to predict benefit from early invasive strategy in patients with unstable angina and non-ST elevations myocardialinfarction. JAMA 2001; 286: 2405-2412.

136. EPISTENT Investigators: Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998; 352: 87-92.

137. Wallentin L, Lagerqvist B, Husted S, Konty F, Stahle E, Swahn E: Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary- artery disease: The FRISC II invasive randomized trial. FRISC II Investigators. Fast Revascularization during Instability in Coronary artery disease. Lancet 2000; 359: 9-16.

138. Scull GS, Martin JS, Weaver WD, Every NR for the MITI investigators: Early angiography versus conservative treatment in patients with non-ST elevation acute myocardial infarction. J Am Coll Cardiol 2000; 35: 895-902.

139. Simoons M: GUSTO IV-ACS Study. In: CD ROM “Highlights from the XXIInd Congress of the European Society of Cardiology”. Amsterdam, Prous Science, 2000.

140. EPISTENT Investigators: Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999; 354: 2019-2024.

141. PRISM-PLUS Study Investigators: Inhibition of platelet glycoprotein IIb/IIIa receptor with Tirofiban in unstable angina and non-Q-wave myocardial infarction. New Engl J Med 1998; 338: 1488-1497.

142. The Pursuit Trial Investigators: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-443.

143. Topol EJ, Mark DB, Lincoff AM, Cohen E, Burton J, Kleiman N, et al: Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomized trial. Lancet 1999; 354: 2019-2024.

144. Spacek R, Widimsky P, Straka Z, Jiresova E, Dvorak J, Polasek R, et al: Value of first day angiography/angioplasty in evolving non-ST segment elevation myocardial infarction: an open multicenter randomized trial. The VINO Study. Eur Heart J 2002; 23: 230-238.

145. Murillo H, Ayala F, Almazan A, Madrid R, Rangel A, Valdespino A, et al: Angioplastía coronaria transluminal percutánea. Experiencia del Hospital de Especialidades del Centro Médico “La Raza”, IMSS. Arch Inst Cardiol Méx 1993; 63: 523-527.

146. Gaspar JH, Ban Hayashi E, Villavicencio R, de la Garza PJ, Gil M, Martínez-Ríos MA: Éxito primario en angioplastía coronaria transluminal: experiencia reciente del Instituto Nacional de Cardiología [1991–1992]. Arch Inst Cardiol Méx 1992; 62: 499-505.

147. Villavicencio R, González HP, López JV, Zavala EA, Ban-Hayashi E, Gaspar J, Gil MM, Martínez-Ríos MA: Angioplastía coronaria con sistema “Monorail” a través de catéteres diagnósticos 6 French. Arch Inst Cardiol Méx 1994; 64: 29-35.

148. Vallejo E, Peña-Duque MA, Noroño O, Ban-Hayashi E, Gaspar J, Villavicencio R, Martínez RMA: Fenómeno de no-reflujo: incidencia y características clínicas en una serie de casos. Arch Inst Cardiol Méx 1998; 68: 247-252.

149. Lupi-Herrera E, Matínez-Sánchez C, Lasses LA: Tratamiento de los síndromes isquémicos agudos. PAC Cardio-1 [B-3]. Sociedad Mexicana de Cardiología. México. 1998.

150. Gaspar HJ, Luna J: El tratamiento intervencionista de la cardiopatía isquémica. PAC Cardio-1 [C-4]. México. Sociedad Mexicana de Cardiología. 1998.

151. Eng-Ceceña L, Gaxiola-López E: Tratamiento del Infarto Agudo del miocardio con onda Q: de la reperfusión a la prevención. PLAC Cardio-3 [libro 3]. Sociedad Mexicana de Cardiología-Sociedad Interamericana de Cardiología. México, Intersistemas SA de CV. 2001: 141-152.

152. De la Llata MR, Rivera AJJ, Eidt LG, Farrell CJ, Palomo VJ, Gaspar HJ, et al: Cardiología Intervencionista en la Cardiopatía Isquémica. PLAC Cardio-3 [libro 11]. Sociedad Mexicana de Cardiología-Sociedad Interamericana de Cardiología. México, Intersistemas SA de CV. 2002: 723-752.

153. Gaspar HJ: Lesión de Tronco: ¿Territorio de la Angioplastia? Arch Inst Cardiol Méx 2000; 70: 7-8.

154. Morice MC, Serruys PW, Sousa E, Fajadet J, Ban-Hayashi E, Perin M, et al for the Ravel study Group: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.

155. Eid-Lidt G, Villavicencio RF, Ponce de León RS, Gaspar HJ, Luna GJ, Ban-Hayashi E, et al: Comparative Trial of stent -like balloon angioplasty versus coronary stenting for acute myocardial infarction. Cathet Cardiovasc Intervent 2001; 53: 149-154.

156. Kwok OH, Prpic R, Gaspar JH, Mathey DG, Escobar A, Goldar-Najafi A, et al: Angiographic outcome after intracoronary X-sizer helical atherectomy and thrombectomy: First use in humans. Cathet Cardiovasc Intervent 2002; 55: 133-139.

157. Favaloro RG: Landmarks in the development of coronary artery bypass surgery. Circulation 1998; 98: 466-478.

158. Rahimtoola SH, Nunley D, Grunkemeier G, Tepley J, Lambert L, Starr A: Ten-year survival after coronary bypass surgery for unstable angina. N Engl J Med 1983; 308: 676-681.

159. Scott SM, Dupree RH, Sharma GA, Luchi RJ: VA study of unstable angina. 10 year results show duration of surgical advantage for patients with impaired ejection fraction. Circulation 1994; 90: II120-II123.

160. Pocock SJ, Henderson RA, Rickards AF, Hampton JR, King III SB, Hamm CW, et al: Meta-analysis of randomized trials comparing coronary angioplasty with bypass surgery. Lancet 1995; 346: 1184-1189.

161. Writing Group for the Bypass Angioplasty Revascularization Investigation [BARI] Investigators: Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease: amulticenter randomized trial. JAMA 1997; 277: 715-721.

162. The Bypass Angioplasty Revascularization Investigation [BARI] Investigators: Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. [erratum appears in N Engl J Med 1997; 336: 147] N Engl J Med 1996; 335: 217-225.

163. CABRI Trial Participants: First-year results of CABRI [Coronary Angioplasty versus Bypass Revascularization Investigation]. Lancet 1995; 346: 1179-1184.

164. Weintraub WS, Stein B, Kosinski A, Douglas JS, Ghazzai ZMB, Jones EL, et al: Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessels coronary artery disease. J Am Coll Cardiol 1998; 31: 10-19.

165. Detre KM, Guo P, Holubkov R, Calif RM, Sopko G, Bach R, et al: Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation [BARI]. Circulation 1999; 99: 633-640.

166. Yussuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al: Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomized trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. [erratum appears in Lancet 1994; 344: 1446] Lancet 1994; 344: 563-570.

167. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group: Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. N Engl J Med 1984; 311: 1333-1339.

168. Coronary Artery Surgery Study [CASS]: A randomized trial of coronary artery bypass surgery. Survival data. Circulation 1983; 68: 939-950.

169. De Feyter PJ, Serruys PW, Arnold A, Simoons ML, Wijns W, Geuskens R, et al: Coronary angioplasty of the unstable angina related vessels in patients with multivessel disease. Eur Heart J 1986; 7: 460-467.

170. Careaga-Reyna G, Salazar-Garrido D, Argüero SR: Revascularización miocárdica versus angioplastía coronaria transluminal percutánea para el tratamiento de la cardiopatía isquémica. Gac Méd Méx 2002; 138: 133-137.

171. Careaga RG, Santaella M, Esparza J, Argüero SR: Revascularización miocárdica sin circulación extracorpórea. Cir Ciruj 1998; 66: 85-88.

172. Second Joint Task Force of European and other Societies on coronary prevention: Prevention of coronary heart disease in clinical practice: recommendation. Eur Heart J 1998; 19: 1434-1503.

173. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, et al: ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 1999; 33: 2092-2197.

174. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzime inhibitor, ramipril, on cardiovascular events in hight-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.

175. Dracup K, Alonso AA, Atkins JM, Bennett NM, Braslow A, Clark LT, et al: The physician’s role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program. Ann Intern Med 1997; 126: 645-651.

176. Van Domburg RT, Miltenburg-van Ziji AJ, Veerhoek RJ, Simoons ML: Unstable angina: good long-term outcome after a complicated early course. J Am Coll Cardiol 1998; 31: 1534-1539.

177. Frasure-Smith N, Lesperance F, Talajic M: Depression and 18-month prognosis after myocardial infarction. [erratum appears in Circulation 1998; 97: 708] Circulation 1995; 91: 999-1005.

178. Randomised trial of cholesterol lowering in 4,444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study [4S]. Lancet 1994; 344: 1383-1389.

179. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001-1009.

180. Flaker GC, Warnica JW, Sacks FM, Moye LA, Davis BR, Rouleau JL, et al: Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. J Am Coll Cardiol 1999; 34: 106-112.

181. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, et al: When to start cholesterol-lowering therapy in patients with coronary heart disease. Circulation 1997; 95: 1683-1685.

182. Dupuis J, Tardif JC, Cernacek P, Theroux P: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE [Reduction of Cholesterol in Ischemia and Function of the Endotelium] trial. Circulation 1999; 99: 3227-3233.

183. Daly LE, Mulcahy R, Graham IM, Hickey N: Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction. Br Med J [Clin Res Ed] 1983, 287: 324-326.

184. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction [DIGAMI study]: effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.

185. American Diabetes Association: Standards of medical care for patients with diabetes mellitus [position statement]. Diabetes Care 1999; 22 Suppl 1: S32-41.

186. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation [BARI]. Circulation 1997; 96: 1761-1769.

187. Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, Liberman HA, et al: Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995; 91: 979-989.

188. Held PH, Teo KK, Yusuf S: Effects of beta blockers, calcium channel blockers, nitrates and magnesium in acute myocardial infarction and unstable angina. Capítulo 3 en: E Topol E. Textbook of Interventional Cardiology. 2nd Ed. Philadelphia PA. WB Saunders Co 1994. P. 46-59.

189. Julian DG, Camm AJ, Frangin G, Janse MJ, Muñoz A, Schwartz PJ, Simon P: Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarction Amiodarone Trial Investigators. Lancet 1997; 349: 667-674.

190. Cairns JA, Conolly SJ, Roberts R, Gent M: Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature despolarizations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349: 675-682.

191. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R for Grupo de Estudio de la Sobrevida en la Insuficiencia Cardíaca en Argentina [GESICA]: Randomized trial of low-dose amiodarone in severe congestive heart failure. Grupo de estudio de la sobrevida en la insuficiencia cardíaca en Argentina [GESICA]. Lancet 1994; 344: 493-498.

192. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77-82.

193. Lytle BW, Loop FD, Taylor PC, Goormastic M, Stewart RW, Novoa R, et al: The effect of coronary reoperation on the survival of patients with stenoses in saphenous vein bypass grafts to coronary arteries. J Thorac Cardiovasc Surg 1993; 105: 605-612.

194. Lytle BW, Loop FD, Taylor PC, Simpfendorfer C, Kramer JR, Ratliff NB, et al: Vein graft disease: the clinical impact of stenoses in saphenous vein bypass to coronary arteries. J Thorac Cardiovasc Surg 1992; 103: 831-840.

195. Ivanov J, Weisel RD, David TE, Naylor CD: Fifteen-year trends in risk severity and operative mortality in elderly patients undergoing coronary artery bypass graft surgery. Circulation 1998; 97: 673-680.

196. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.

197. Chen L, Theroux P, Lesperance J, Shabani F, Thibault B, de Guise P: Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery. J Am Coll Cardiol 1996; 28: 1493-1499.

198. Kushi LH, Folsom AR, Primeas RJ, Mink PJ, Wu Y, Bostick RM: Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med 1996; 334: 1156-62.

199. Constant J: Alcohol, ischemic Heart disease, and the French Parades. Cline Cardiol 1997; 20: 420-424.

200. Mosque L, Grande SM, Judson D, King K, Limacher M, Oparil S, et al: Guide to preventive cardiology for women. Circulation 1999; 99: 2480-2484.

201. Lundberg V, Stegmayor B, Asplund K, Eliasson M, Huhtasaari F: Diabetes as a risk factor for myocardial infarction: population and gender perspectives. J Inter Med 1997; 241: 485-492.

202. Mosca L, Grundy SM, Judelson D, King K, Limacher M, Oparil S, et al: Guide to preventive cardiology for women. Circulation 1999; 99: 2480-2484.

203. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273(3): 199-208.

204. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC: Vitamin E consumption and the risk of coronary disease in men. N Engl J Med 1993; 32:1450-1459.

205. Hennekens CH, Albert CM, Godfried SL: Adjunctive drug therapy of acute myocardial infarction-Evidence from clinical trials. N Engl J Med 1996; 335: 1660-1667.

206. Hambrecht R, Wolf A, Gielen S, Linke A, Hofer J, Erbs S, et al: Effect of exercise in coronary endothelial function in patients with coronary artery disease. N Engl J Med 2000; 342: 454-460.

207. Hammar N, Romelsjo A, Alfredson L: Alcohol consumption, drinking pattern and acute myocardial infarction. A case referent study based on the Swedish Twin Register. J Intern Med 1997; 241: 125-131.

208. Kannel WB, D’Agostino RB, Belanger AJ: Fibrinogen as a risk factor for coronary artery disease. Ann Epidemiol 1992; 2:457-466.